AUTOLUS THERAPEUTICS PLC Stock Price, News & Analysis

Autolus Therapeutics (Nasdaq: AUTL) announced significant clinical data at the European Hematology Association Congress from June 9-12, 2022. Key highlights include:

• AUTO4: Shows promising activity for T cell lymphoma with favorable safety profiles.
• AUTO1/22: Demonstrates strong remission rates in children with B-ALL, even those unresponsive to existing CAR T therapies.
• Obe-cel: Exhibits sustained efficacy in B-NHL and emerging activity in Primary CNS Lymphoma.

A conference call will take place on June 13, 2022, at 7:30 AM EST to discuss these findings.

Autolus Therapeutics plc (Nasdaq: AUTL) has announced its Annual General Meeting (AGM) to be held on June 28, 2022, in London. The official notice for shareholders details the meeting's agenda, which includes ordinary and special resolutions. The company will announce the results of the voting via a press release following the AGM. Autolus is focused on developing advanced T cell therapies for cancer treatment, utilizing proprietary technologies to create targeted therapies aimed at hematological malignancies and solid tumors.

Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in the Jefferies Healthcare Conference in New York City on June 9, 2022. CEO Dr. Christian Itin will engage in a Fireside Chat from 9:00 to 9:30 am ET. The company will also hold one-on-one investor meetings at the event. An audio webcast of the Fireside Chat will be available on Autolus' website, with an archived version accessible for a limited period post-conference. Autolus specializes in programmed T cell therapies aimed at treating various cancers.

Autolus Therapeutics (AUTL) has announced the online publication of four abstracts for the European Hematology Association (EHA) Congress, scheduled for June 9-12, 2022. Notable presentations include early clinical data for AUTO4 targeting peripheral T cell lymphoma and AUTO1/22 for pediatric B-cell acute lymphoblastic leukemia. CEO Christian Itin expressed optimism about the early safety and efficacy data, particularly for the lead asset, obe-cel. A conference call on June 13, 2022, will detail these findings and propose next steps for the pipeline.

Autolus Therapeutics (NASDAQ: AUTL) reported operational and financial results for Q1 2022, revealing a net loss of $37.1 million, or $(0.41) per share. Cash reserves decreased to $268.6 million from $310.3 million as of December 31, 2021. Significant updates include the successful futility analysis of the FELIX clinical trial for obe-cel in adult B-cell Acute Lymphoblastic Leukemia, which received RMAT designation from the FDA. Initial data from the trial is expected in late 2022. Autolus also continues its pipeline developments, with upcoming presentations at the EHA Congress in June.

Autolus Therapeutics plc (Nasdaq: AUTL) announced the presentation of three innovative cell programming approaches at the American Society of Gene & Cell Therapy (ASGCT) from May 16-19, 2022. Dr. Martin Pule emphasized the importance of enhancing T cell therapy through improved targeting and activity for better patient outcomes. The posters include:

• Enhancing CAR T Cell Therapy Using Cytokine Receptors
• Fas-CD40 Chimera for Better T Cell Effectiveness in Solid Tumors
• Minocycline as a Tuning Control for CAR T Cell Activation

These advancements aim to enhance cancer treatment outcomes.

Autolus Therapeutics plc (Nasdaq: AUTL) has received RMAT designation from the FDA for its lead gene therapy, obe-cel, designed for adult patients with relapsed/refractory B-Acute Lymphocytic Leukemia (ALL). This designation recognizes the therapy's potential to fulfill unmet medical needs and facilitates the drug development process. obe-cel has also received PRIME and ILAP designations in Europe. The ongoing FELIX Phase 2 trial aims to enroll 140 patients across multiple centers. This milestone underscores the importance of obe-cel in addressing critical treatment gaps in adult B-ALL.

Autolus Therapeutics plc (Nasdaq: AUTL) will report its Q1 2022 financial results and operational highlights on May 5, 2022, before U.S. markets open. A conference call and webcast will follow at 8:30 am ET/1:30 pm BST for management to discuss the results and provide a business update. Investors can access the presentation and call via Autolus' website or by dialing provided numbers for U.S. and international listeners. The call will be available for replay for one week.

Autolus Therapeutics (AUTL) has received Orphan Medical Product Designation from the European Medicines Agency for its CAR T therapy, obe-cel, aimed at treating acute lymphoblastic leukemia (ALL). This milestone follows a similar designation from the FDA in 2019. The designation offers benefits such as fee reductions and ten years of market exclusivity post-approval. Ongoing clinical trials for obe-cel focus on its efficacy and safety in adult ALL patients, with first Phase 2 data expected later this year, indicating progress in addressing urgent treatment needs.